Load independent impairment of reverse remodeling after valve replacement in hypertensive aortic stenosis patients

International Journal of Cardiology

Volumn 170, Issue 3, 2014, Pages 324-330

  Gavina, Cristina ^a   Falcão Pires, Inês ^a   Rodrigues, João ^b   Marinho, Benjamim ^b   Gonçalves, Nadia ^a   Lopes, Ricardo ^b   Amorim, Mário Jorge ^a,b   Almeida, Jorge ^b   Pinho, Paulo ^a,b   Gonçalves, Alexandra ^b   Rocha Gonçalves, Francisco ^a   Leite Moreira, Adelino ^a,b  

^a University of Porto   (Portugal)

^b Centro Hospitalar Universitário de São João   (Portugal)

Author keywords

Aortic stenosis; Aortic valve replacement; Extracellular matrix; Hypertension; Left ventricular mass; Reverse remodeling

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

AGED; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; COLLAGEN TYPE I GENE; COLLAGEN TYPE III GENE; CONTROLLED STUDY; CTGF GENE; DISEASE ASSOCIATION; DISEASE SEVERITY; EUROSCORE; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MMP2 GENE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TGF BETA1 GENE; TIMP2 GENE; UPREGULATION; VERY ELDERLY;

AORTIC STENOSIS; AORTIC VALVE REPLACEMENT; EXTRACELLULAR MATRIX; HYPERTENSION; LEFT VENTRICULAR MASS; REVERSE REMODELING;

AGED; AORTIC VALVE STENOSIS; COLLAGEN TYPE I; COLLAGEN TYPE III; CONNECTIVE TISSUE GROWTH FACTOR; EXTRACELLULAR MATRIX; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84890989898     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.11.006     Document Type: Article

References (45)

1. F. Antonini-Canterin, G. Huang, and E. Cervesato et al. Symptomatic aortic stenosis: does systemic hypertension play an additional role? Hypertension 41 2003 1268 1272
2. K. Linhartova, J. Filipovsky, R. Cerbak, G. Sterbakova, I. Hanisova, and V. Beranek Severe aortic stenosis and its association with hypertension: analysis of clinical and echocardiographic parameters Blood Press 16 2007 122 128
3. Rieck AE, Cramariuc D, Staal EM, Rossebo AB, Wachtell K, Gerdts E. Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a seas substudy). J Hypertens.28:377-383
4. R. Querejeta, B. Lopez, and A. Gonzalez et al. Increased collagen type i synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis Circulation 110 2004 1263 1268
5. J.F. Spann, A.A. Bove, G. Natarajan, and T. Kreulen Ventricular performance, pump function and compensatory mechanisms in patients with aortic stenosis Circulation 62 1980 576 582
6. M.L. Marcus, D.B. Doty, L.F. Hiratzka, C.B. Wright, and C.L. Eastham Decreased coronary reserve: a mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries N Engl J Med 307 1982 1362 1366
7. H.P. Krayenbuehl, O.M. Hess, E.S. Monrad, J. Schneider, G. Mall, and M. Turina Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement Circulation 79 1989 744 755
8. R.E. Zybach-Benz, B.C. Aeschbacher, and M. Schwerzmann Impact of left ventricular hypertrophy late after aortic valve replacement for aortic stenosis on cardiovascular morbidity and mortality Int J Cardiol 109 2006 41 47
9. J. Lessick, D. Mutlak, W. Markiewicz, and S.A. Reisner Failure of left ventricular hypertrophy to regress after surgery for aortic valve stenosis Echocardiography 19 2002 359 366
10. K. Taniguchi, T. Takahashi, and K. Toda et al. Left ventricular mass: impact on left ventricular contractile function and its reversibility in patients undergoing aortic valve replacement Eur J Cardiothorac Surg 32 2007 588 595
11. S. Heymans, B. Schroen, and P. Vermeersch et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart Circulation 112 2005 1136 1144
12. R.M. Lang, M. Bierig, and R.B. Devereux et al. Recommendations for chamber quantification: a report from the American society of echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology J Am Soc Echocardiogr 18 2005 1440 1463
13. S.F. Nagueh, C.P. Appleton, and T.C. Gillebert et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography J Am Soc Echocardiogr 22 2009 107 133
14. J.R. Wilson, N. Reichek, and J. Hirshfeld Noninvasive assessment of load reduction in patients with asymptomatic aortic regurgitation Am J Med 68 1980 664 674
15. I. Falcao-Pires, N. Goncalves, and C. Gavina et al. Correlation between plasma levels of apelin and myocardial hypertrophy in rats and humans: possible target for treatment? Expert Opin Ther Targets 14 2010 231 241
16. B.R. Lindman, S.V. Arnold, and J.A. Madrazo et al. The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis Circ Heart Fail 4 2011 286 292
17. I. Falcao-Pires, N. Hamdani, and A. Borbely et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness Circulation 124 2011 1151 1159
18. O. Lund, L.H. Kristensen, and U. Baandrup et al. Myocardial structure as a determinant of pre- and postoperative ventricular function and long-term prognosis after valve replacement for aortic stenosis Eur Heart J 19 1998 1099 1108
19. O. Lund Preoperative risk evaluation and stratification of long-term survival after valve replacement for aortic stenosis. Reasons for earlier operative intervention Circulation 82 1990 124 139
20. O. Bech-Hanssen, K. Caidahl, B. Wall, P. Myken, S. Larsson, and I. Wallentin Influence of aortic valve replacement, prosthesis type, and size on functional outcome and ventricular mass in patients with aortic stenosis J Thorac Cardiovasc Surg 118 1999 57 65
21. Bech-Hanssen O, Aljassim O, Houltz E, Svensson G. The relative contribution of prosthetic gradients, systemic arterial pressure, and pulse pressure to the left ventricular pressure in patients with aortic prosthetic valves. Eur J Echocardiogr.12:37-45
22. Z. Hachicha, J.G. Dumesnil, and P. Pibarot Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis J Am Coll Cardiol 54 2009 1003 1011
23. K. Imanaka, O. Kohmoto, S. Nishimura, Y. Yokote, and S. Kyo Impact of postoperative blood pressure control on regression of left ventricular mass following valve replacement for aortic stenosis Eur J Cardiothorac Surg 27 2005 994 999
24. T. Bove, Y. Van Belleghem, K. Francois, F. Caes, H. Van Overbeke, and G. Van Nooten Stentless and stented aortic valve replacement in elderly patients: factors affecting midterm clinical and hemodynamical outcome Eur J Cardiothorac Surg 30 2006 706 713
25. O. Lund, K. Emmertsen, I. Dorup, F.T. Jensen, and C. Flo Regression of left ventricular hypertrophy during 10 years after valve replacement for aortic stenosis is related to the preoperative risk profile Eur Heart J 24 2003 1437 1446
26. M. Gaudino, F. Alessandrini, and F. Glieca et al. Survival after aortic valve replacement for aortic stenosis: does left ventricular mass regression have a clinical correlate? Eur Heart J 26 2005 51 57
27. D.B. Johnson, and L.J. Dell'Italia Cardiac hypertrophy and failure in hypertension Curr Opin Nephrol Hypertens 5 1996 186 191
28. W.S. Post, M.G. Larson, and D. Levy Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study Circulation 90 1994 179 185
29. S.B. Harrap, A.F. Dominiczak, and R. Fraser et al. Plasma angiotensin ii, predisposition to hypertension, and left ventricular size in healthy young adults Circulation 93 1996 1148 1154
30. J. Burns, S.G. Ball, G. Worthy, A.D. Struthers, D.A. Mary, and J.P. Greenwood Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance J Hypertens 30 2012 2039 2046
31. O.M. Hess, M. Ritter, J. Schneider, J. Grimm, M. Turina, and H.P. Krayenbuehl Diastolic stiffness and myocardial structure in aortic valve disease before and after valve replacement Circulation 69 1984 855 865
32. S. Hein, E. Arnon, and S. Kostin et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms Circulation 107 2003 984 991
33. F.G. Spinale Matrix metalloproteinases: regulation and dysregulation in the failing heart Circ Res 90 2002 520 530
34. E.E. Creemers, J.P. Cleutjens, J.F. Smits, and M.J. Daemen Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89 2001 201 210
35. J. Fielitz, S. Hein, and V. Mitrovic et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease J Am Coll Cardiol 37 2001 1443 1449
36. J. Fielitz, M. Leuschner, and H.R. Zurbrugg et al. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis J Mol Med 82 2004 809 820
37. M. Flamant, S. Placier, and C. Dubroca et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling Hypertension 50 2007 212 218
38. S.H. Ahmed, L.L. Clark, and W.R. Pennington et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease Circulation 113 2006 2089 2096
39. R.S. Friese, F. Rao, and S. Khandrika et al. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease Clin Exp Hypertens 31 2009 521 533
40. G. Derosa, A. D'Angelo, and L. Ciccarelli et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension Endothelium 13 2006 227 231
41. M.H. Tayebjee, S. Nadar, A.D. Blann, D. Gareth Beevers, R.J. MacFadyen, and G.Y. Lip Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian cardiac outcomes trial (ascot) Am J Hypertens 17 2004 764 769
42. Yasmin, C.M. McEniery, and S. Wallace et al. Matrix metalloproteinase-9 (mmp-9), mmp-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness Arterioscler Thromb Vasc Biol 25 2005 372
43. I.K. Onal, B. Altun, E.D. Onal, A. Kirkpantur, S. Gul Oz, and C. Turgan Serum levels of mmp-9 and timp-1 in primary hypertension and effect of antihypertensive treatment Eur J Intern Med 20 2009 369 372
44. E.S. Monrad, O.M. Hess, T. Murakami, H. Nonogi, W.J. Corin, and H.P. Krayenbuehl Time course of regression of left ventricular hypertrophy after aortic valve replacement Circulation 77 1988 1345 1355
45. O. Lund, and M. Erlandsen Changes in left ventricular function and mass during serial investigations after valve replacement for aortic stenosis J Heart Valve Dis 9 2000 583 593